Outcome of Deep Brain Stimulation (DBS) for the Treatment of Parkinson’s Disease in Terms of Improvement in MDS-UPDRS Scale Over 5 Years

  • Khalid Mahmood Punjab Institute of Neurosciences (PINS), Lahore
  • Omair Afzal Ali Punjab Institute of Neurosciences (PINS), Lahore
  • Adeeb-ul- Hassan Punjab Institute of Neurosciences (PINS), Lahore
  • Imran Ali Punjab Institute of Neurosciences (PINS), Lahore
Keywords: Deep Brain Stimulation, Globus Pallidus, Subthalamic Nucleus

Abstract

Background & Objective:  Parkinson’s disease (PD) is the second most common Neurodegenerative disorder after Alzheimer’s disease. There are several surgical procedures for advanced PD, but amongst all deep brain stimulation has proven to be safest and effective. The objective of this study was to see the outcome of DBS for the treatment of PD in terms of improvement in MDS UPDRS over 5 years.

Material and Methods:  44 patients were included in study from Oct 2014 to Sep 2019. History, examination was carried out, and preoperative MDS-UPDRS (Movement Disorder Society Unified Parkinson’s Disease Rating Scale) was recorded. Postoperative improvement in MDS-UPDRS score was assessed at first Programming, 2nd week, and 6th week and at 3rd month.

Results:  At baseline the mean, the MDS – UPDRS (Part-I) score was 14.20 ± 0.61 and at the end of 3rd month, the mean score was 11.18 ± 0.47 respectively. At baseline the mean, the MDS – UPDRS (part-II) score was 18.99 ± 0.70 and at the end of 3rd month, the mean score was 13.01 ± 0.57, respectively. At baseline the mean, the MDS – UPDRS (part-III) score was 45.19 ± 0.90 and at the end of 3rd month, the mean score was 25.15 ± 1.20 respectively. At baseline the mean, the MDS – UPDRS (part-IV) score was 10.18 ± 0.87 and at the end of 3rd month, the mean score was 3.85 ± 1.03, respectively. 

Conclusion:  The Deep Brain Stimulation (DBS) is safe and effective in the management of PD.

References

Elbaz A, Carcaillon L, Kab S.Moisan F. Epidemiology of Parkinson's disease. Rev Neurol. 2016; 172: 14-26.
2. Chen, S-Y, Tsai, S-T. The Epidemiology of Parkinson's Disease. Tzu ChiMedical Journal, 2010; 22: 73-81.
3. Pouratian N, Thakkar, S Kim, W Bronstein, J. M. Deep brain stimulation for the treatment of Parkinson’s disease efficacy and safety. Degenerative Neurol Neuromuscular Dis, 2012: 1-16.
4. Benabid AL, Chabardes S. SeigneuretE. Deep-brain stimulation in Parkinson's disease: long-term efficacy and safety – What happened this year? Curr Opin Neurol. 2005; 18: 623-30.
5. Follett K. A, Weaver F. M, Stern M, Hur K, Harris, C. L Luo, P.Marks Jr, W. J. Rothlind, J. Sagher, O. Moy C. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med. 2010; 362: 2077-2091.
6. Fahn S. Unified Parkinson's disease rating scale. J Parkinsons Dis. 1987.
7. Kelvin L. Chou, Jennifer L. Taylor, Parag G. Patil, The MDS–UPDRS tracks motor and non–motor improvement due to subthalamic nucleus deep brain stimulation in Parkinson disease Parkinsonism Relat Disord. 2013; 19 (11).
8. Rodriguez-Oroz, M Obeso, J Lang, Houeto, J.-L, Pollak, P. Rehncrona, et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain, 2005; 128: 2240-2249.
9. Goetz CG. Tilley BC. Shaftman SR. Stebbins GT, Fahn, S. et al. Movement Disorder Society – sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS – UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008; 23: 2129-2170.
10. Zesiewicz T. Sullivan, K. Arnulf, I. Chaudhuri, K. Morgan JC, et al.W Practice parameter: treatment of nonmotor symptoms of Parkinson disease report of the quality standards subcommittee of the american academy of neurology. Neurology, 2010; 74: 924-931.
Published
2021-01-01
Section
Original Article